new tirzepatide drug Unlikely to Exacerbate DR in First Year of Treatment FDA approves new weight loss

Gastrointestinal adverse effects represent the most common tolerability challenges with semaglutide, affecting approximately 4050% of patients according to FDA prescribing information

Deficiency in B12 can lead to demyelination, resulting in neurological symptoms such as numbness, tingling, impaired coordination, and cognitive decline

How They Work: The Key Difference This is where things get interesting

If B12 levels are low, treatment is usually simple

Only when we fully understand the underlying factors can we truly help you achieve significant, sustainable weight loss

Early assessment helps determine whether these symptoms are related to the medication or another underlying condition requiring urgent care